BWA
KROS icon

Basecamp Wealth Advisors’s Keros Therapeutics KROS Stock Holding History

Basecamp Wealth Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82K Buy
170
+29
+21% +$323 ﹤0.01% 1390
2026
Q1 		$1.56K Buy
141
+108
+327% +$1.67K ﹤0.01% 1456
2025
Q4 		$672 Buy
+33
New +$579 ﹤0.01% 1579

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Basecamp Wealth Advisors's KROS Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Keros Therapeutics (KROS) stake by 21% in Q2 2026, buying an estimated $323 and bringing the position to 170 shares worth $1.82K. The position accounts for ﹤0.01% of the portfolio, ranked #1390.

Basecamp Wealth Advisors first reported a position in KROS in Q4 2025 and has held it in 3 quarters since. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Basecamp Wealth Advisors held 170 shares of Keros Therapeutics worth $1.82K as of Q2 2026.
  • Basecamp Wealth Advisors bought 29 Keros Therapeutics shares in Q2 2026, an estimated $323.
  • Keros Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1390 holding.
  • Basecamp Wealth Advisors first reported a position in Keros Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.